Overview

Safety and Efficacy Study of NV-101 in Dental Patients

Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was: - to determine if NV-101 accelerates recovery from numbness compared to placebo - to evaluate safety of NV-101
Phase:
Phase 2
Details
Lead Sponsor:
Novalar Pharmaceuticals, Inc.
Treatments:
Phentolamine